Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2021-11-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
中天国富证券有限公司关于新乡拓新药业股份有限公司使用部分超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal opinion from a sponsoring securities firm regarding the use of part of the company's over-raised funds to permanently supplement working capital. It references regulatory rules about the management and use of raised funds, details the amount of funds raised and used, and confirms compliance with relevant laws and procedures. The document includes audit references and board meeting approvals but does not contain financial statements or detailed financial data itself. It is a regulatory compliance and verification statement related to capital use, not a full financial report or earnings release. Given the content and length (2054 characters), it fits best as a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2021-11-11 Chinese
关于使用自有资金向子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of its own funds to increase capital in its wholly-owned subsidiary. It details the amount of capital increase, board and supervisory committee approvals, financial status of the subsidiary, and the impact and risks of the capital increase. There are no financial statements or comprehensive financial reports included, only a description of the capital increase transaction and related approvals. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising or capital structure changes. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is CAP.
2021-11-11 Chinese
关于变更股份总数、注册资本、公司类型及修改公司章程
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company regarding changes in total shares, registered capital, company type, and amendments to the company charter, along with the completion of related industrial and commercial registration changes. It references approvals from the China Securities Regulatory Commission and details about share issuance and listing on the Shenzhen Stock Exchange. The document is a formal public announcement of corporate structural changes and regulatory approvals, not a full financial report or detailed management discussion. It is also relatively short (1622 characters) and does not contain financial statements or detailed financial analysis. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-11-11 Chinese
关于使用部分闲置募集资金用于暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of part of its idle raised funds to temporarily supplement working capital. It includes details about the fundraising, approvals from the board, supervisory board, independent directors, and the sponsor institution. The document does not contain financial statements or detailed financial performance data but rather describes a financing-related decision and compliance with regulatory requirements. The document length is about 3,069 characters, which is relatively short and focused on a specific capital usage update. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2021-11-11 Chinese
第四届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the decisions made during the fourth meeting of the fourth Supervisory Board, including approvals related to the use of raised funds, cash management, and capital increases to subsidiaries. The document includes voting results and references to related announcements but does not contain financial statements or detailed financial data. It is a formal announcement of board meeting resolutions rather than a full management report or financial report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2021-11-11 Chinese
股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock trading fluctuations for the company 新乡拓新药业股份有限公司. It details the stock price movements, investigation results, and risk warnings related to the stock price volatility. There is no financial data, no report attached or referenced as being published, and no mention of an annual or quarterly report. The document is a regulatory announcement about stock trading behavior and company disclosures, fitting the category of a Regulatory Filing (RNS). The document length is short (1447 characters), and it is clearly an announcement rather than a full report or financial statement.
2021-11-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.